Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 2/20 | 0.61 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.47 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 11/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | HTR3A | P46098 | 2/20 | 0.40 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4516401 | 0.88 | PARP1 (0.48) | RIPK1PIM1PARP1AURKARPS6KB1 | |
| Hydrochloric Acid SCHEMBL4507414 | 0.85 | RIPK1 (0.44) | RIPK1PKN1PKN2PIM1PARP1 | |
| SCHEMBL4503780 | 0.81 | PARP1 (0.56) | RIPK1PARP1HTR3AHTR4 | |
| SCHEMBL4504445 | 0.76 | PIM1 (0.47) | PKN1PKN2PIM1PARP1AURKA | |
| SCHEMBL4504259 | 0.76 | RIPK1 (0.47) | RIPK1PARP1CRBNHTR3AHTR4 | |
| SCHEMBL4503785 | 0.75 | RIPK1 (0.53) | RIPK1PKN1PKN2PARP1PARP2 | |
| SCHEMBL17697629 | 0.75 | CRBN (0.59) | RIPK1PKN1PKN2PARP1CRBN | |
| Hydrochloric Acid SCHEMBL4505592 | 0.73 | KDM4E (0.43) | PIM1CHEK1CHEK2HTR4 | |
| SCHEMBL4490880 | 0.72 | PDGFRB (0.58) | PIM1CHEK1HTR3A | |
| SCHEMBL4495617 | 0.72 | PARP1 (0.56) | PARP1HTR3AHTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7517875-B2 | Piperidine derivatives having CCR3 antagonism | TEIJIN LIMITED (JP) | 2009-04-14 | — | — | US | disclosed |
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | TEIJIN LIMITED, A JAPANESE BODY CORPORATE (JP) | 2007-02-08 | — | — | US | disclosed |
| EP-1502916-A1 | PIPERIDINE DERIVATIVES HAVING CCR3 ANTAGONISM | TEIJIN LIMITED (JP) | 2005-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032525-A1 | Piperidine derivatives having ccr3 antagonism | CCR3, CCR1, CCR4 | RIPK1 1974/4885PKN1 3509/4885PKN2 3902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.